Expanding TRP Therapy into Neuroendocrine Tumours: Targeting SSTR2 with 212Pb

By | 20 June 2025
  • Discussing Orano Med’s unique approach to TAT with 212Pb
  • Presenting the latest updates on 212Pb-DOTAMTATE 
  • Exploring Orano Med’s portfolio of 212Pb-based TATs